GHRS
GH Research PLC
Company Overview
| Mkt Cap | $1.01B | Price | $15.82 |
| Volume | 165.94K | Change | +1.02% |
| P/E Ratio | -25.8 | Open | $15.55 |
| Revenue | -- | Prev Close | $15.66 |
| Net Income | $-39.0M | 52W Range | $7.98 - $20.50 |
| Div Yield | N/A | Target | $33.50 |
| Overall | 39 | Value | -- |
| Quality | 21 | Technical | 58 |
No chart data available
About GH Research PLC
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Latest News
Analysts Offer Insights on Healthcare Companies: GH Research (GHRS) and COMPASS Pathways (CMPS)
Analysts Are Bullish on Top Healthcare Stocks: GH Research (GHRS), Viking Therapeutics (VKTX)
RBC Capital Remains a Buy on GH Research (GHRS)
GH Research Showcases Positive GH001 Phase 2b Data in Treatment-Resistant Depression at ACNP 2026
RBC Capital Sticks to Their Buy Rating for GH Research (GHRS)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GHRS | $15.82 | +1.0% | 165.94K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |